Scholar Rock rises as drug helps preserve muscle in study of patients with obesity

** Shares of drug developer Scholar Rock Holding Corp SRRK.O gain 14.22% to $35.58 premarket

** Co says its experimental drug helped patients with obesity preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's LLY.N weight-loss treatment Zepbound

** Patients receiving co's drug apitegromab with LLY's drug showed a 54.9% preservation of lean mass versus Zepbound alone over 24 weeks

** Patients receiving the combination lost more fat mass than those on LLY's tirzepatide alone

** Up to last close, stock down ~28% YTD